The full clinical data used in this study contains information that may lead to the identification of the individuals. We have provided a supplementary file that contains minimal data essential to the results reported in our study. For other researchers to request the full dataset, we should get additional approval from the Institutional Review Board of Seoul National University Hospital for sharing the data (<irb@snuh.org>).

Introduction {#sec005}
============

Breast cancer is the most common female malignancy and is the second common cause of cancer death in women.\[[@pone.0173721.ref001]\] Due to its high incidence, breast cancer is also a major health issue for women with medical co-morbidities. The presence of co-morbidities pose can influence the decision on the use of the various treatment modalities. Furthermore, several studies have reported a significant increase in cancer mortality and post-treatment morbidity in cancer patients with pre-existing health conditions.\[[@pone.0173721.ref002], [@pone.0173721.ref003]\]

Recent studies have suggested that the breast cancer patients who has significant co-morbidities tend to have increased treatment-related complication and deaths, and also carry higher risk for overall and cancer mortalities.\[[@pone.0173721.ref004]--[@pone.0173721.ref007]\] Researchers have suggested the lower rates of adjuvant therapy as well as the natural course of the pre-existing medical conditions was the potential link between the increased risk of death and the presence of co-morbidities.\[[@pone.0173721.ref008]\] However, some reported that elderly patients with co-morbidities have worse survival outcome despite the similar rates of adjuvant therapy administration.\[[@pone.0173721.ref009]\]

Population-based studies on the association of the co-morbidity and survival have advantages of less biased sample collection and large number of patients. However, they may carry weakness in identifying details of the individual patient's adjuvant therapy information depending on the database they use.\[[@pone.0173721.ref010]\] In this study, we investigated the relationship between the breast cancer survival and the presence of co-morbidities in a relatively large cohort of patients treated in a single institution. We determined the degree of their co-morbidity by using the American Society of Anesthesiologists (ASA) classifications assessed at the time of the initial surgery.

Materials and methods {#sec006}
=====================

Patients and analysis {#sec007}
---------------------

The medical records of 2,501 patients who underwent surgery for primary breast cancer from June 2006 to June 2010 at Seoul National University Hospital were retrospectively reviewed. The data of patients were obtained from the web-based database of Seoul National University Hospital Breast Care Center.\[[@pone.0173721.ref011]\]

We excluded patients with stage IV disease at the time of the diagnosis. Each patient's pre-existing co-morbidities was assessed by using the ASA classification. Briefly, ASA I includes patients who are healthy, non-smoking, and minimal alcohol use at the time of surgery. ASA II includes patients with mild systemic disease such as well-controlled hypertension or diabetes. ASA III includes patients with severe systemic disease such as poorly controlled hypertension or diabetes, chronic obstructive pulmonary disease, and end-stage renal disease receiving regular dialysis. The ASA classification was determined at the preoperative interview with the anesthesiologists. Recurrence was defined as distant metastasis or loco-regional recurrence. The information of death date was obtained from the Korean National Statistical Office.

Survival outcome was estimated by the Kaplan-Meier method and compared across groups using the log-rank. For multivariate analysis, a Cox proportional hazards ratio model was used to estimate the adjusted hazard ratio for significance. All analyses were carried out using SPSS (version 19.0; SPSS Inc). The statistical significance was assumed at p \< 0.05.

Ethics and consent {#sec008}
------------------

This study approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 1405-088-580). Written informed consents were taken prior to surgery in all patients to register their information in the database. The review and analysis of the collected information were separately approved. All procedures were done in accordance with the Declaration of Helsinki.

Results {#sec009}
=======

The characteristics of included patients are summarized in the [Table 1](#pone.0173721.t001){ref-type="table"}. The median follow-up period of 2,501 analyzed patients was 71 months. There were 1,792 (71.6%), 665 (36.6%) and 44 (1.8%) patients in ASA I, II, and III groups, respectively. A total of 95 (3.8%) deaths, 72 breast cancer-related deaths (2.9%), and 269 (10.8%) recurrences (loco-regional recurrence and distant metastasis) occurred during the follow-up periods. Ninety-seven percent of the patients who received adjuvant chemotherapy completed the recommended cycles.

10.1371/journal.pone.0173721.t001

###### Characteristics among 2,501 patients underwent surgery for breast cancer, 2006--2010.

![](pone.0173721.t001){#pone.0173721.t001g}

  Characteristics                                                                               Number (Percent)      
  ------------------------------------------- ------------------------------------------------- --------------------- --------------
  Age                                                                                           49.76 ± 10.14         
  Median follow-up period (month)                                                               71.00                 
  Gender                                      Male                                              6 (0.2%)              
                                              Female                                            2495 (99.8%)          
  Operation type (breast)                     Mastectomy                                        834 (33.3%)           
                                              Breast conserving surgery                         1667 (66.7%)          
  Operation type (axilla)                     Axillary lymph node dissection                    985 (39.4%)           
                                              Sentinel lymph node biopsy                        1414 (56.5%)          
                                              Not done                                          102 (4.1%)            
  ASA[^a^](#t001fn001){ref-type="table-fn"}   1                                                 1792 (71.6%)          
                                              2                                                 665 (26.6%)           
                                              3                                                 44 (1.8%)             
  Chemotherapy                                Not done                                          940 (37.6%)           
                                              Done                                              1555 (62.2%)          
                                              Unknown                                           6 (0.2%)              
  Adjuvant Radiotherapy                       Not done                                          714 (28.5%)           
                                              Done                                              1774 (70.9%)          
                                              Unknown                                           13 (0.5%)             
  Adjuvant hormone therapy                    Not done                                                                869 (34.7%)
                                              Done                                              Tamoxifen             1082 (43.2%)
                                                                                                Aromatase inhibitor   517 (20.7%)
                                              Unknown                                                                 33 (1.3%)
  Neoadjuvant chemotherapy                    Not done                                                                2210 (88.4%)
                                              Done                                                                    291 (11.6%)
  Hormone receptor                            Estrogen receptor                                 Positive              1637 (65.5%)
                                                                                                Negative              853 (34.1%)
                                                                                                Unknown               11 (0.4%)
                                              Progesterone receptor                             Positive              1321 (52.8%)
                                                                                                Negative              1169 (46.7%)
                                                                                                Unknown               11 (0.4%)
                                              Her-2 (FISH)                                      Positive              520 (20.8%)
                                                                                                Negative              1680 (67.1%)
                                                                                                Unknown               301 (12.0%)
  Subtype                                     HR[^b^](#t001fn002){ref-type="table-fn"}+HER-2-   1247 (49.9%)          
                                              HR+HER-2+                                         218 (8.7%)            
                                              HR-HER-2+                                         301 (12.0%)           
                                              HR-HER-2-                                         433 (17.3%)           
                                              Unknown                                           302 (12.1%)           
  Histologic grade                            1                                                 153 (6.1%)            
                                              2                                                 779 (31.1%)           
                                              3                                                 976 (39.0%)           
                                              Unknown                                           593 (23.7%)           
  Event                                       Death                                             95 (3.8%)             
                                              Recur (distant metastasis + loco-regional)        269 (10.8%)           
                                              Breast cancer related death                       72 (2.9%)             
  Stage                                       0[^c^](#t001fn003){ref-type="table-fn"}           314 (12.6%)           
                                              I                                                 890 (35.6%)           
                                              II                                                928 (37.1%)           
                                              III                                               369 (14.8%)           
  T stage                                     Tis                                               314 (12.6%)           
                                              1                                                 1061 (42.4%)          
                                              2                                                 937 (37.5%)           
                                              3                                                 158 (6.3%)            
                                              4                                                 31 (1.2%)             
  N stage                                     0                                                 1617 (64.7%)          
                                              1                                                 577 (23.1%)           
                                              2                                                 204 (8.2%)            
                                              3                                                 103 (4.1%)            

^a^ American Society of Anesthesiologists

^b^ Hormone receptor

^c^ Ductal carcinoma in situ

The presence of co-morbidities was significantly associated with various clinicopathologic variables as shown in the [Table 2](#pone.0173721.t002){ref-type="table"}. Patients with ASA II or ASA III classification had more advanced tumors, were more likely to receive mastectomy, and were less likely to undergo adjuvant therapies with the exception of adjuvant hormonal therapy. There was no significant difference in the rates of patients who failed to complete the recommended cycles of chemotherapy according to the ASA groups. Survival analysis showed that the presence of co-morbidity had significant adverse effects on overall survival, breast cancer-specific survival, and breast cancer recurrence ([Fig 1](#pone.0173721.g001){ref-type="fig"}). In Cox multivariate regression analysis, the severity of co-morbidity was significantly associated with both overall survival and disease-free survival ([Table 3](#pone.0173721.t003){ref-type="table"})

![Disease-free survival, overall-survival, and breast cancer-specific survival according to the ASA status.\
Kaplan-Meier survival curves for the disease-free survival (A), overall survival (B), and breast cancer-specific survival (C) are shown (*P*-value is analyzed with comparing to ASA 1 group).](pone.0173721.g001){#pone.0173721.g001}

10.1371/journal.pone.0173721.t002

###### Characteristics in each American Society of Anesthesiologists (ASA) group.

![](pone.0173721.t002){#pone.0173721.t002g}

  ASA[^a^](#t002fn001){ref-type="table-fn"}                                                                           I               II              III             P-value
  ------------------------------------------- ------------------------------------------------- --------------------- --------------- --------------- --------------- ---------
  Patients                                                                                                            1792 (71.6%)    665 (26.6%)     44 (1.8%)       
  Age                                                                                                                 47.53 ± 9.18    54.94 ±10.19    62.27 ±9.04     \<0.001
  Follow-up period (month)                                                                                            68.99 ± 17.89   65.75 ± 18.24   62.48 ± 19.76   \<0.001
  Gender                                      Male                                                                    2 (0.1%)        4 (0.6%)        0 (0.0%)        .083
                                              Female                                                                  1790 (99.9%)    661 (99.4%)     44 (100%)       
  Operation type (breast)                     Mastectomy                                                              561 (31.3%)     250 (37.6%)     23 (52.3%)      \<0.001
                                              Breast conserving surgery                                               1231 (68.7%)    415 (62.4%)     21 (47.7%)      
  Operation type (axilla)                     Axillary lymph node dissection                                          667 (37.2%)     295 (44.4%)     23 (52.3%)      .003
                                              Sentinel lymph node biopsy                                              1043 (58.2%)    352 (52.9%)     19 (43.2%)      
                                              Not done                                                                82 (4.6%)       18 (2.7%)       2 (4.5%)        
  Chemotherapy                                Not done                                                                649 (36.2%)     266 (40.0%)     25 (56.8%)      .018
                                              Done                                                                    1140 (63.6%)    396 (59.5%)     19 (43.2%)      
                                              Unknown                                                                 3 (0.2%)        3 (0.5%)        0 (0.0%)        
  Adjuvant Radiotherapy                       Not done                                                                470 (26.2%)     223 (33.5%)     21 (47.7%)      \<0.001
                                              Done                                                                    1314 (73.3%)    438 (65.9%)     22 (50.0%)      
                                              Unknown                                                                 8 (0.4%)        4 (0.6%)        1 (2.3%)        
  Adjuvant hormone therapy                    Not done                                                                609 (34.0%)     245 (36.8%)     15 (34.1%)      \<0.001
                                              Done                                              Tamoxifen             888 (49.6%)     185 (27.8%)     9 (20.5%)       
                                                                                                Aromatase inhibitor   271 (15.1%)     227 (34.1%)     19 (43.2%)      
                                              Unknown                                                                 24 (1.3%)       8 (1.2%)        1 (2.3%)        
  Neoadjuvant Chemotherapy                    Not done                                                                1605 (89.6%)    564 (84.8%)     41 (93.2%)      .003
  Done                                                                                          187 (10.4%)           101 (15.2%)     3 (6.8%)                        
  Hormone receptor                            Estrogen receptor                                 Positive              1181 (65.9%)    427 (64.2%)     29 (65.9%)      .936
                                                                                                Negative              603 (33.6%)     235 (35.3%)     15 (34.1%)      
                                                                                                Unknown               8 (0.4%)        3 (0.5%)        0 (0.0%)        
                                              Progesterone receptor                             Positive              988 (55.1%)     310 (46.6%)     23 (52.3%)      .006
                                                                                                Negative              796 (4.4%)      352 (52.9%)     21 (47.7%)      
                                                                                                Unknown               8 (0.4%)        3 (0.5%)        0 (0.0%)        
                                              Her-2 (FISH)                                      Positive              354 (19.8%)     159 (23.9%)     7 (15.9%)       .111
                                                                                                Negative              1226 (68.4%)    421 (63.3%)     33 (75.0%)      
                                                                                                Unknown               212 (11.8%)     85 (12.8%)      4 (9.1%)        
  Subtype                                     HR[^b^](#t002fn002){ref-type="table-fn"}+HER-2-                         919 (51.3%)     302 (45.4%)     26 (49.9%)      .246
                                              HR+HER-2+                                                               146 (8.1%)      70 (10.5%)      2 (4.5%)        
                                              HR-HER-2+                                                               208 (11.6%)     88 (13.2%)      5 (11.4%)       
                                              HR-HER-2-                                                               307 (17.1%)     119 (17.7%)     7 (15.9%)       
                                              Unknown                                                                 212 (11.8%)     86 (12.9%)      4 (9.1%)        
  Histologic grade                            1                                                                       108 (6.0%)      41 (6.2%)       4 (9.1%)        .801
                                              2                                                                       554 (30.9%)     210 (31.6%)     15 (34.1%)      
                                              3                                                                       691 (38.6%)     269 (40.5%)     16 (36.4%)      
                                              Unknown                                                                 439 (24.5%)     145 (21.8%)     9 (20.5%)       
  Event                                       Death                                                                   51 (2.8%)       38 (5.7%)       6 (13.6%)       \<0.001
                                              Recur (distant metastasis + loco-regional)                              180 (10.0%)     80 (12.0%)      9 (20.5%)       .041
                                              Breast cancer related death                                             43 (2.4%)       25 (3.8%)       4 (9.1%)        .009
  Stage                                       0[^c^](#t002fn003){ref-type="table-fn"}                                 237 (13.2%)     71 (10.7%)      6 (13.6%)       .004
                                              I                                                                       664 (37.1%)     214 (32.2%)     12 (27.3%)      
                                              II                                                                      655 (36.6%)     258 (38.8%)     15 (34.1%)      
                                              III                                                                     236 (13.2%)     122 (18.3%)     11 (25.0%)      
  T stage                                     Tis                                                                     237 (13.2%)     71 (10.7%)      6 (13.6%)       .058
                                              1                                                                       781 (43.6%)     264 (39.7%)     16 (36.4%)      
                                              2                                                                       655 (36.6%)     263 (39.5%)     19 (43.2%)      
                                              3                                                                       101 (5.6%)      54 (8.1%)       3 (6.8%)        
                                              4                                                                       18 (1.0%)       13 (2.0%)       0 (0.0%)        
  N stage                                     0                                                                       1191 (66.5%)    401 (60.3%)     25 (56.8%)      .019
                                              1                                                                       405 (22.6%)     161 (24.2%)     11 (25.0%)      
                                              2                                                                       134 (7.5%)      64 (9.6%)       6 (13.6%)       
                                              3                                                                       62 (3.5%)       39 (5.9%)       2 (4.5%)        

^a^ American Society of Anesthesiologists.

^b^ Hormone receptor.

^c^ Ductal carcinoma in situ.

10.1371/journal.pone.0173721.t003

###### Multivariate and univariate analysis of mortality and recurrence in American Society of Anesthesiologists (ASA) groups.

![](pone.0173721.t003){#pone.0173721.t003g}

                                                                                                 Overall survival   Cancer specific survival   Disease free survival                                                                                                                                                                            
  ------------------------------------------- -------------------------------------------------- ------------------ -------------------------- ----------------------- --------- ------- -------- ------- --------- ------- -------- ------- -------- ------- ------- ------- -------- ------- ------- ------- -------- ------- ------- ------- --------
  Age                                                                                            0.005              1.029                      1.009                   1.049     0.653   1.005    0.984   1.026     0.573   1.007    0.984   1.03                                      0.008   0.983   0.971   0.996    0.001   0.976   0.963   0.99
  ASA[^a^](#t003fn001){ref-type="table-fn"}   I                                                  0                                                                               0.005                              0.011                             0.003                            0.015                            0.002                   
                                              II                                                 0.001              2.084                      1.369                   3.173     0.096   1.471    0.933   2.318     0.074   1.567    0.957   2.565    0.399   1.241   0.751   2.051    0.066   1.281   0.984   1.669    0.077   1.29    0.973   1.709
                                              III                                                0                  5.169                      2.217                   12.049    0.002   4.454    1.753   11.321    0.007   4.116    1.477   11.469   0.001   6.399   2.222   18.429   0.014   2.315   1.185   4.524    0.001   3.356   1.661   6.78
  Neoadjuvant chemotherapy                                                                       0                  4.701                      3.099                   7.133     0.307   1.39     0.739   2.618     0       6.19     3.897   9.833    0.058   1.931   0.978   3.811    0       3.218   2.459   4.21     0.024   1.58    1.063   2.349
  Mastectomy                                                                                     0                  3.469                      2.292                   5.252     0.059   1.601    0.983   2.607     0       3.127    1.947   5.023    0.108   1.561   0.907   2.685    0       1.791   1.409   2.278    0.063   1.297   0.986   1.706
  T stage                                     Tis                                                0                                                                               0.012                                                                                                 0                                0.046                   
                                              1                                                  0.118              4.997                      0.665                   37.55     0.172   4.407    0.525   36.967    0                                 0.059                            0.253   1.384   0.792   2.417    0.582   1.217   0.606   2.443
                                              2                                                  0.007              15.232                     2.1                     110.499   0.051   8.582    0.995   74.004    0       3.81     1.878   7.731    0.396   1.396   0.646   3.02     0       3.05    1.787   5.206    0.128   1.782   0.847   3.75
                                              3                                                  0                  54.575                     7.395                   402.782   0.012   17.698   1.899   164.896   0       17.047   8.113   35.821   0.017   3.208   1.232   8.354    0       7.182   4.002   12.886   0.024   2.619   1.133   6.053
                                              4                                                  0                  83.319                     10.249                  677.318   0.022   15.849   1.494   168.118   0       24.283   8.823   66.831   0.125   2.691   0.76    9.523    0       9.005   4.039   20.074   0.097   2.413   0.854   6.819
  N stage                                     0                                                  0                                                                               0                                  0                                 0                                0                                0.003                   
                                              1                                                  0.013              2.043                      1.165                   3.582     0.193   1.542    0.804   2.958     0.019   2.3      1.15    4.599    0.45    1.345   0.624   2.901    0.002   1.582   1.175   2.13     0.753   1.059   0.742   1.512
                                              2                                                  0                  6.616                      3.827                   11.437    0.001   3.373    1.681   6.767     0       9.75     5.151   18.457   0       4.142   1.874   9.154    0       3.359   2.398   4.705    0.02    1.661   1.083   2.549
                                              3                                                  0                  13.234                     7.602                   23.039    0       4.484    2.127   9.454     0       14.899   7.526   29.495   0.002   3.916   1.65    9.29     0       5.451   3.708   8.014    0.001   2.248   1.376   3.671
  HG                                          1                                                  0                                                                               0.004                              0                                 0.006                            0                                0                       
                                              2                                                  0.287              3.001                      0.396                   22.718    0.495   2.034    0.264   15.645    0.575   1.807    0.229   14.262   0.966   1.046   0.13    8.409    0.109   2.119   0.846   5.304    0.247   1.728   0.685   4.359
                                              3                                                  0.016              11.443                     1.589                   82.393    0.116   5.078    0.669   38.556    0.027   9.305    1.288   67.216   0.266   3.165   0.415   24.144   0       6.049   2.486   14.719   0.003   4.004   1.592   10.068
  Subtype                                     HR[^b^](#t003fn002){ref-type="table-fn"}+/HER-2-   0                                                                               0.018                              0                                 0.055                            0                                0.564                   
                                              HR+/HER-2+                                         0.497              0.661                      0.2                     2.184     0.195   0.449    0.134   1.505     0.655   0.717    0.166   3.091    0.205   0.385   0.088   1.686    0.02    1.644   1.082   2.499    0.598   1.123   0.729   1.731
                                              HR-/HER-2+                                         0.001              2.858                      1.551                   5.268     0.989   0.993    0.385   2.56      0       3.794    1.912   7.528    0.837   1.124   0.367   3.449    0       2.246   1.597   3.158    0.356   1.303   0.743   2.285
                                              HR-/HER-2-                                         0                  5.198                      3.201                   8.442     0.067   2.246    0.944   5.344     0       5.846    3.32    10.294   0.127   2.258   0.793   6.433    0       2.417   1.796   3.254    0.202   1.423   0.828   2.447
  Chemotherapy                                                                                   0.021              1.724                      1.084                   2.741     0       0.313    0.173   0.566     0.058   1.79     0.982   3.263                                     0       2.191   1.639   2.931    0.043   0.654   0.433   0.987

^a^ American Society of Anesthesiologists.

^b^ Hormone receptor.

We tested the prognostic impact of co-morbidity according to the various clinical and pathologic factors. The increased hazard ratio of the severe co-morbidity was most evident in patients who did not receive adjuvant therapies ([Fig 2A](#pone.0173721.g002){ref-type="fig"}). Indeed, the patients with ASA III classification showed significantly worse outcome in tumor recurrence and deaths when they did not receive adjuvant therapies ([Fig 2B](#pone.0173721.g002){ref-type="fig"}). This prognostic association was not seen in patients who underwent adjuvant therapies. We further investigated the incidence of serious adverse effect during adjuvant therapy in 2,367 patients who underwent adjuvant therapy including 36 patients in ASA III classification. The incidence of grade 3 and 4 adverse effects was not significantly different according to the ASA classification.

![Survival of patients according to their ASA status and the use of adjuvant therapies.\
The relative risks of recurrence in ASA II and ASA III patients compared to ASA I in various subgroups of studied patients are shown in Fig 2A. Survival outcomes of patients who received adjuvant therapies (B, upper panels) and who did not receive adjuvant therapies (B, lower panels).](pone.0173721.g002){#pone.0173721.g002}

Discussion {#sec010}
==========

In the present study, we show that breast cancer patients with pre-existing co-morbidities have higher risk of recurrences and deaths by using the clinical data from 2,501 operable breast cancer patients treated in single institution. The significant association between the presence of co-morbidity and the poor treatment outcome was mostly seen in patients who did not receive postoperative adjuvant therapies. Our results suggest that conservative administration of adjuvant therapies in these patients may have resulted in the increased rate of recurrences and deaths.

Our results are in line with several previous observations on the relationship between the co-morbidity and survival in many cancer types including breast cancer.\[[@pone.0173721.ref012], [@pone.0173721.ref013]\] These studies have consistently shown that women with significant pre-existing co-morbidity have shorter overall survival. However, there are conflicting results on the association between the presence of co-morbidity and the risk of recurrence or metastasis. Based on the cancer registry data in Denmark, Land et al \[[@pone.0173721.ref010]\] have reported that the patients with higher degree of co-morbidity had significantly lower rates of recurrences despite their increased risk of deaths. Gold et al \[[@pone.0173721.ref014]\], on the other hand, have shown that omission of appropriate adjuvant therapies can wosen the treatment outcome even in early breast cancer patients. Our data adds evidence to the increased risk of recurrence in patients with significant co-morbidities.

It is a challenging issue for clinicians to determine the optimal treatment approaches for breast cancer patients with severe co-morbidities. For surgical treatment, axillary node dissection or nodal staging is often minimized in elderly patients with co-morbidities. On the other hand, mastectomy over breast conservation is often recommended to minimize the need for the adjuvant radiation to the chest wall. We also observed a significantly higher rate of mastectomy in patients with severe co-morbidities. Patient's pre-existing co-morbidities and their functional status also influence the decision of adjuvant systemic therapies.\[[@pone.0173721.ref015]\] While it is rational to omit systemic therapy in patients with severe co-morbidity who are vulnerable to serious adverse effects, it also raises oncologic concerns since the adjuvant cytotoxic therapies can reduce the rate of recurrence and mortality in elderly breast cancer patients.\[[@pone.0173721.ref016]\] In our data, the significant association between the co-morbidity and increased risk of recurrence was only seen in patients who did not receive adjuvant therapies suggesting that omitting adjuvant therapy in patients with severe co-morbidity can result in disease recurrences. Additionally, we did not observe an increased risk of developing serious adverse effects in patients with severe co-morbidity who underwent adjuvant therapies. Similary to our observation, Klepin et al \[[@pone.0173721.ref017]\] reported no difference in treatment-related toxicities according to the co-morbidity status in patients undergoing cytotoxic chemotherapy.

Our study carries several important limitations. We used ASA classification and did not adopt the Charlson Comorbidity Index which is a commonly-used tool in assessing the degree of co-morbidity. However, ASA classification is well-correlated with Charlson Comorbidity Index and it has been shown to predict treatment-related outcomes.\[[@pone.0173721.ref018]\] Another limitation is the small number of ASA II and III patients that may weaken the present findings. Finally, a retrospective nature of this study warrants a prospective and multicenter observational study to validate the association between the patient's co-morbidity status and oncologic outcomes.

Conclusion {#sec011}
==========

In this study, high comorbidity was related to higher rates of mortality and recurrence in breast cancer patients. Especially, in high comorbidity patients group who did not receive adjuvant therapy, the rate of mortality and recurrence was higher. Considering the relatively low rates of serious adverse effects in high co-morbidity patients who received adjuvant therapies, active use of adjuvant therapies in selected patients may improve survival outcomes in breast cancer patients with severe co-morbidities.

Supporting information {#sec012}
======================

###### The basic clinical datasets used for the analysis.

The S1 file.xls contains information of co-morbidity and survival of the studied patients.

(XLSX)

###### 

Click here for additional data file.
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